Results 41 to 50 of about 1,043 (146)

Are Tetrapleura tetraptera Phytochemicals Druggable Against SARS‐CoV‐2 Papain‐Like Protein? A Computational Approach

New Zealand Journal of Botany, Volume 64, Issue 1, March 2026.
SARS‐CoV2 Omicron and its substrains are still a critical global health issue and extremely contagious, even with widespread vaccination efforts. Hospitalizations and mortality rates linked to these variants are still prevalent. Current therapeutic options face challenges, including low effectiveness, suboptimal pharmacokinetics, and drug resistance ...
Frank Eric Tatsing Foka, Hazel Tumelo Mufhandu   +1 more
wiley   +1 more source

CMV Preventive and Treatment Studies in Children Undergoing Haematopoietic Stem Cell Transplant: A Systematic Review

Reviews in Medical Virology, Volume 36, Issue 2, March 2026.
ABSTRACT Cytomegalovirus (CMV) is one of the most important infectious causes of morbidity and mortality in children undergoing haematopoietic stem cell transplant (HSCT). However, the evidence for preventing and treating CMV disease in children in this context remains limited. We sought to review the current available evidence regarding the prevention
Lara Fusani, Eleonora Fusco, Mariana Fonseca, Judith Breuer, Kanchan Rao, Luisa Galli, Alasdair Bamford, Seilesh Kadambari   +7 more
wiley   +1 more source

Management of Cytomegalovirus Infections in the Era of the Novel Antiviral Players, Letermovir and Maribavir

Infectious Disease Reports
Cytomegalovirus (CMV) infections may increase morbidity and mortality in immunocompromised patients. Until recently, standard antiviral drugs against CMV were limited to viral DNA polymerase inhibitors (val)ganciclovir, foscarnet and cidofovir with a ...
Jocelyne Piret, Guy Boivin
doaj   +1 more source

Combined Treatment with Host-Directed and Anticytomegaloviral Kinase Inhibitors: Mechanisms, Synergisms and Drug Resistance Barriers

Pharmaceutics, 2023
Despite the availability of currently approved antiviral drugs, infections with human cytomegalovirus (HCMV) still cause clinically challenging, sometimes life-threatening situations.
Markus Wild, Dubravka Karner, Jan Eickhoff, Sabrina Wagner, Jintawee Kicuntod, William Chang, Peter Barry, Stipan Jonjić, Tihana Lenac Roviš, Manfred Marschall   +9 more
doaj   +1 more source

HHV‐8/KSHV in Solid Organ Transplantation: Current Gaps of Knowledge and Future Directions

Transplant Infectious Disease, Volume 28, Issue 2, March/April 2026.
Risk mitigation strategies, including donors/recipients screening, DNAemia monitoring in recipients at risk, CNI‐to‐mTOR inhibitors switch, antivirals, and rituximab for KICS, may mitigate the impact of HHV‐8/KSHV infection in SOT. This review provides an update on KICS, identifies research gaps, and summarizes advances in screening and management ...
Alessandra Mularoni, Andrea Cona, Malgorzata Mikulska, Francesca Pecoraro, Carlotta Piazza, Elda De Vita, Giada Pietrosi, Matteo Bulati, Tiziana Lazzarotto, Mario Luppi   +9 more
wiley   +1 more source

Large Language Models for Clinical Trial Protocol Assessments

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 393-402, February 2026.
The purpose was to evaluate the utility of large language models (LLMs) for reviewing the statistical analysis plan (SAP) and pharmacokinetics–pharmacodynamics (PK–PD) components of clinical trial protocols. Clinical trial protocols and SAPs were obtained from clinicaltrials.gov for a testbed of 15 small‐molecule drugs, biologics, and global antibiotic
Euibeom Shin, Amruta Gajanan Bhat, Murali Ramanathan   +2 more
wiley   +1 more source

Case Report: Approaches for managing resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplantation recipients

Frontiers in Pediatrics
The instructional case is a pediatric haploidentical TCRαβ+/CD19+ depleted allogeneic hematopoietic cell transplantation recipient who developed early onset CMV infection, which was complicated by resistant CMV (both UL97 and UL54) and successfully ...
Eunkyung Song, Eunkyung Song
doaj   +1 more source

Stereoselective Phosphorylation of Cyclopropavir by pUL97 and Competitive Inhibition by Maribavir [PDF]

Antimicrobial Agents and Chemotherapy, 2010
ABSTRACT Human cytomegalovirus (HCMV) is a widespread pathogen that can cause severe disease in immunologically immature and immunocompromised individuals. Cyclopropavir (CPV) is a guanine nucleoside analog active against human and murine cytomegaloviruses in cell culture and efficacious in mice by oral administration.
Gentry, Brian G., Kamil, Jeremy P., Coen, Donald M., Zemlicka, Jiri, Drach, John C.   +4 more
openaire   +4 more sources

Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance [PDF]

The Journal of Infectious Diseases, 2007
The cytomegalovirus (CMV) UL97 kinase inhibitor maribavir (MBV) is undergoing clinical antiviral trials. Two clinical CMV isolates serially passaged in cell culture under MBV showed >20-fold increases in MBV resistance after the development of the UL97 mutation V353A in one of the isolates and of T409M in the other.
Sunwen, Chou, Laura C Van, Wechel, Gail I, Marousek   +2 more
openaire   +2 more sources

Intestinal and Multivisceral Transplantation: Where We Stand Today

Pediatric Transplantation, Volume 30, Issue 1, January 2026.
ABSTRACT Intestinal and multivisceral transplantation has evolved from an experimental to a life‐saving procedure for children and adults with complications of gut failure (GF). Suboptimal long‐term outcomes of transplant elicit recent advances in surgical and medical gut rehabilitation along with the introduction of glucagon‐like peptide‐2 (GLP‐2 ...
Mohamed Maklad, Mohammed Osman, Mariam Ismail, Tetsuya Tajima, Kadakkal Radhakrishnan, Masato Fujiki   +5 more
wiley   +1 more source